comparemela.com

Latest Breaking News On - Engitix ltd - Page 1 : comparemela.com

Engitix Announces Appointment of Matthew Edwards Ph.D., as SVP Discovery and Emma Huang Ph.D., as VP Data Sciences

Engitix Announces Appointment of Matthew Edwards Ph.D., as SVP Discovery and Emma Huang Ph.D., as VP Data Sciences
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United-kingdom
London
City-of
Mike-platt
Gemma-huang
Matthew-edwards
Christopher-stevenson
Giuseppe-mazza
Sue-charles
Division-of-medicine
Engitix-ltd
Linkedin

Engitix Announces Appointment of Sonia Quaratino, M.D., Ph.D., as Independent Non-executive Director

Engitix Announces Appointment of Sonia Quaratino, M.D., Ph.D., as Independent Non-executive Director
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states
London
City-of
United-kingdom
Sonia-quaratino
Sue-charles
Eduardo-bravo
Charles-consultants
Mike-platt
Giuseppe-mazza
Merck-serono
Division-of-medicine

Head-To-Head Survey: ANI Pharmaceuticals (NASDAQ:ANIP) and Morphic (NASDAQ:MORF)

ANI Pharmaceuticals (NASDAQ:ANIP – Get Rating) and Morphic (NASDAQ:MORF – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk. Institutional and Insider Ownership 59.7% of ANI Pharmaceuticals shares are […]

Minnesota
United-states
Waltham
Massachusetts
Canada
Baudette
Morphic-holding-inc
Abbvie-biotechnology-ltd
Janssen-pharmaceuticals-inc
Morphic-company-profile-get-rating
Pharmaceuticals-company-profile-get-rating

Engitix Announces Expanded Collaboration and Licensing Agreement with Takeda to Develop New Anti-Fib

Collaboration combines Engitix’s unique human extracellular matrix (ECM) platform with Takeda’s expertise in gastroenterology research and development (R&D) and commercialisationAgreement with Takeda for the discovery and development of novel therapeutics for inflammatory bowel disease (IBD) builds on existing colla.

United-kingdom
London
City-of
Giuseppe-mazza
Mike-platt
Exscalate-domp
Gareth-hicks
Digestive-health
University-college-london
Division-of-medicine
Engitix-ltd
Linkedin

vimarsana © 2020. All Rights Reserved.